Aarti Pharmalabs Limited AARTIPHARM NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.aartipharmalabs.com

Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.

Market & Price

Market Cap

₹5,740.90 Cr

Current Price

₹633.25

High / Low (52W)

₹960.26 / ₹591.95

Beta

Valuation

Stock P/E

32.90

Industry PE

37.60

Forward P/E

PEG Ratio

Book Value

₹234.28

Price to Book

2.70

P/S

3.14

EV/EBITDA

15.84

Dividend Yield

0.63%

Profitability & Returns

ROCE

11.00%

ROE

8.49%

ROA

6.02%

Profit Margin

9.55%

Op Margin

17.50%

EPS (Latest Qtr)

₹6.74

EPS (TTM)

₹19.25

Balance Sheet & Liquidity

Debt/Equity

0.37

Quick Ratio

0.64

Current Ratio

1.49

Debt

₹793.72 Cr

Total Assets

₹3,481.71 Cr

Current Assets

₹1,397.29 Cr

Working Capital

₹459.72 Cr

Ownership

Promoter Holding

44.54%

Chg in Prom Hold

1.93%

FII / Inst Holding

12.54%

Chg in FII Hold

0.09%

Financial Snapshot

Enterprise Value

₹6,526.96 Cr

Total Revenue (TTM)

₹1,829.19 Cr

EBITDA

₹412.16 Cr

Free Cash Flow

₹-162.33 Cr

Operating Cash Flow

₹261.93 Cr

Shares Outstanding

₹9.07 Cr

Gross Margin

54.36%

Payout Ratio

20.78%

Growth (CAGR)

Revenue 5Y

-2.05%

Profit 5Y

-3.35%

Revenue (YoY)

3.30%

Earnings (YoY)

-30.80%

PROS

No notable strengths flagged.

CONS

Revenue declined at -2.0% CAGR over 5 years.
Earnings shrank at -3.3% CAGR over 5 years.
Trading 34.0% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	AARTIPHARM Aarti Pharmalabs Limited NSEPHARMA	633.25	32.90	₹5,740.90 Cr	0.63%	11.00%	8.49%	-2.05%	-3.35%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	537.78 Cr	563.78 Cr	386.19 Cr	418.33 Cr	432.27 Cr	582.64 Cr
Cost of Revenue	-	261.42 Cr	259.65 Cr	169.41 Cr	209.78 Cr	172.66 Cr	283.02 Cr
Gross Profit	-	276.36 Cr	304.13 Cr	216.79 Cr	208.56 Cr	259.62 Cr	299.62 Cr
Operating Expenses	-	170.79 Cr	181.32 Cr	144.34 Cr	158.61 Cr	185.93 Cr	197.66 Cr
Operating Income	-	105.57 Cr	122.81 Cr	72.45 Cr	49.95 Cr	73.69 Cr	101.97 Cr
EBITDA	-	133.64 Cr	144.02 Cr	95.04 Cr	74.13 Cr	104.07 Cr	126.70 Cr
Interest Expense	-	9.97 Cr	6.58 Cr	6.79 Cr	10.67 Cr	12.58 Cr	16.86 Cr
Pretax Income	-	100.63 Cr	114.62 Cr	65.45 Cr	38.69 Cr	62.87 Cr	81.68 Cr
Tax Provision	-	26.64 Cr	26.28 Cr	15.95 Cr	10.77 Cr	14.91 Cr	20.55 Cr
Net Income	-	73.99 Cr	88.34 Cr	49.50 Cr	27.92 Cr	47.96 Cr	61.12 Cr
Diluted EPS	-	8.16	9.74	5.46	3.08	5.29	6.74

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	1,936.00 Cr	1,815.51 Cr	2,115.07 Cr	1,819.44 Cr
Cost of Revenue	-	1,253.97 Cr	1,113.06 Cr	1,076.65 Cr	834.83 Cr
Gross Profit	-	682.04 Cr	702.44 Cr	1,038.42 Cr	984.61 Cr
Operating Expenses	-	402.53 Cr	389.63 Cr	660.95 Cr	686.53 Cr
Operating Income	-	279.51 Cr	312.81 Cr	377.47 Cr	298.08 Cr
EBITDA	-	344.37 Cr	390.94 Cr	474.49 Cr	384.16 Cr
Interest Expense	-	21.05 Cr	17.21 Cr	26.90 Cr	46.90 Cr
Pretax Income	-	260.77 Cr	300.49 Cr	360.69 Cr	232.92 Cr
Tax Provision	-	67.28 Cr	83.59 Cr	88.28 Cr	58.21 Cr
Net Income	-	193.49 Cr	216.90 Cr	272.40 Cr	174.71 Cr
Diluted EPS	-	21.35	23.93	30.04	19.25

Compounded Sales Growth

5 Years:	-2.05%
1 Year:	3.30%

Compounded Profit Growth

5 Years:	-3.35%
1 Year:	-30.80%

Stock Price Performance

1 Year:	-29.61%
6 Months:	-6.79%
3 Months:	-7.81%
1 Month:	-10.70%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	2,244.02 Cr	2,582.11 Cr	2,906.41 Cr	3,481.71 Cr
Current Assets	-	1,163.01 Cr	1,345.64 Cr	1,322.17 Cr	1,397.29 Cr
Cash & Equivalents	-	12.12 Cr	23.63 Cr	6.73 Cr	8.53 Cr
Inventory	-	602.04 Cr	642.86 Cr	587.58 Cr	640.31 Cr
Receivables	-	450.10 Cr	519.34 Cr	575.40 Cr	583.32 Cr
Total Liabilities	-	685.54 Cr	825.07 Cr	916.50 Cr	1,357.10 Cr
Current Liabilities	-	600.62 Cr	694.39 Cr	657.05 Cr	937.57 Cr
Long Term Debt	-	18.35 L	3.88 L	111.26 Cr	185.81 Cr
Total Debt	-	215.31 Cr	285.25 Cr	420.82 Cr	754.36 Cr
Total Equity	-	1,558.49 Cr	1,757.04 Cr	1,989.91 Cr	2,124.60 Cr
Shares Outstanding	-	9.06 Cr	9.06 Cr	9.06 Cr	9.07 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	250.12 Cr	216.35 Cr	330.14 Cr	261.93 Cr
Investing Cash Flow	-	-157.80 Cr	-214.56 Cr	-412.48 Cr	-430.72 Cr
Financing Cash Flow	-	-163.46 Cr	9.72 Cr	65.43 Cr	170.58 Cr
Capital Expenditure	-	-119.66 Cr	-198.79 Cr	-443.88 Cr	-448.31 Cr
Free Cash Flow	-	130.46 Cr	17.57 Cr	-113.74 Cr	-186.38 Cr
Net Change in Cash	-	-71.15 Cr	11.51 Cr	-16.90 Cr	1.80 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	35.2%	38.7%	49.1%	54.1%
Operating Margin %	-	14.4%	17.2%	17.8%	16.4%
Net Margin %	-	10.0%	11.9%	12.9%	9.6%
ROE %	-	12.4%	12.3%	13.7%	8.2%
ROCE %	-	17.0%	16.6%	16.8%	11.7%

Shareholding Pattern

Insiders

44.54%

Institutions

12.54%

Public Float

22.60%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AARTIPHARM

No recent headlines available.

AARTIPHARM · Healthcare